Open AccessA monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells.
Author(s) -
D J FitzGerald,
M C Willingham,
Carol Cardarelli,
Hiroyuki Hamada,
T Tsuruo,
M M Gottesman,
I Pastan
Publication year - 1987
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.84.12.4288
Subject(s) - multiple drug resistance , monoclonal antibody , p glycoprotein , efflux , antibody , toxin , conjugate , biology , drug resistance , microbiology and biotechnology , glycoprotein , immunotoxin , cancer cell , cancer , immunology , biochemistry , genetics , mathematics , mathematical analysis
One form of multidrug resistance is due to the expression of a 170-kDa energy-dependent drug efflux pump called P-glycoprotein in the plasma membranes of human cancer cells. We have prepared conjugates of Pseudomonas toxin with the anti-P-glycoprotein monoclonal antibody MRK-16. These anti-P-glycoprotein-toxin conjugates specifically kill multidrug-resistant human KB cells. Similar conjugates could be useful in cancer therapy to reduce or eliminate multidrug-resistant tumor populations in tumors intrinsically resistant to chemotherapy or in populations that become resistant during combination chemotherapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom